LOS ANGELES, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has achieved its third milestone payment from GlaxoSmithKline LLC ("GSK") related to the issuance of a U.S. patent for detection of BRAF Mutations.
Help employers find you! Check out all the jobs and post your resume.
